The objective of the HELICOVAXOR® project was to develop a novel adjuvanted, multivalent Helicobacter pylori vaccine, which would be ready to enter human clinical trials within 24 months. The key work packages (WP) to achieve this objective are described below. All the work packages produced promising results, but as is often the case in early stage research, there were some surprising outcomes. There is a very promising prototype that key members of the consortium continue to work on.
The different work packages were interlinked and are coordinated as outlined below